We examined the effect of the acetylcholinesterase (ACHE) 
INTRODUCTION
Widely accepted is that the glutamatergic and cholinergic systems are actively involved in the processes of learning and memory. In fact, Li et al. (1997) demonstrated that the NMDA antagonists MK-801 and CGS-19755 significantly augmented scopolamine-induced impairment of memory performance. In addition, Pavlovsky et al. (2003) revealed that the AChE inhibitor pyridostigmine enhanced glutamatergic transmission in hippocampal CA1 neurons.
Previous behavioral studies on metabotropic glutamate receptors by Bianchin and coworkers (1994) showed that ACPD (( S,3 R)-1-aminocyclopentane-l,3-dicarboxylic acid), a selective agonist for group II mGluRs, enhances memory of the avoidance task. In addition, Riedel et al. (2002) suggested that group II mGluRs modulate neural networks involved in conditioning formation. Although these recent studies have described a relation between group II mGluRs and learning and memory, further studies are necessary to (C) Ueda et al. (1979) . The injections (10 tl each) were completed 10 minutes before the acquisition trial, according to the method of Matuoka et al. (1995) . DONP was dissolved in 0.9% saline and injected (0.1-1 mg/kg)subcutaneously 60 minutes before the acquisition trial.
Learning and memory ability was assessed by the step-through-type passive avoidance test using methods modified from Matuoka et al. (1995) . In short, a two-compartment step-through-type passive avoidance apparatus was used. The box was divided into bright (9 9 x 36 cm) and dark compartments (26 26 x 36 cm) by a guillotine door. In each trial, a mouse was placed in the illuminated compartment for a 30-sec habituation period, and then a guillotine door was raised to allow entry into the dark chamber. On the pre-exposure session (data not shown), the step-through latency (the length of time spent in the bright compartment after a habituation period) was measured. Mice that stepped through to the grids of the dark compartment were allowed to remain there for 30 sec without electrical stimulation and were then returned to their home cage. After the measurement of the pre-exposure latency, the acquisition trial was conducted, 10 min after intracistemal drug injection. When the hind legs of the mice entered into the dark chamber, the guillotine door was closed and electrical foot shock (20 V, duration 80 ms, alternating current) was delivered through the grid floor for a total of 3 sec. The time that elapsed before entry into the dark compartment (latency) was recorded. Retention trials were then performed at 24 h after the acquisition trial and the latency was measured for up to 300 sec.
Statistical analysis was performed by one-way analysis of variance (ANOVA) with the Bonferroni/ Dunn post-hoc test. Statistically significant differences between groups are indicated by p < 0.05.
RESULTS AND DISCUSSION
The effects of several doses of DONP, 50 ng DCG-IV (an mGlu 2/3 receptor agonist), and 300 ng LY341495 (an mGlu 2/3 receptor antagonist) on each trail of the step-through performance task are shown in Fig. 1 . One-way ANOVA revealed a significant diffirence among the six treatment groups on the retention trial (F(5, 39) 13.50, p < 0.01).
Additionally, post hoc tests showed that the intracistemal injection of DCG-IV (p < 0.01) or LY341495 (p < 0.01) significantly suppressed the latency of the task compared with that of the vehicle group on the retention trial but not that of the acquisition trial. In addition, no significant difference was found between the DONP and vehicle groups in either trail.
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The enhancement of glutamate release is known to be caused by ACh in hippocampal regions, such as CA1 (Pavlovsky, et al., 2003; Takeda, et al., 2003) or in the dentate gyrus (Wheal, et al., 1980) . The administration of DONP at mg/kg might cause an increase of ACh at synapses, and consequently, the enhancement of glutamate release could counteract the inhibition of the cAMP/PKA signaling pathway induced by DCG-1V via other receptors such as mGlu and 5, or NMDA receptors. In addition, DCG-IV reportedly reduces ACh release in the striatum of rats (Pisani, et al., 2002) ; therefore, the administration of DCG-1V at 50 ng might have also inhibited ACh release in the present study. Together, these findings suggest that the ameliorating effect of donepezil against DCG-IV-induced amnesia is due to an increase in synaptic ACh.
The administration of LY341495 at 300 ng reduced the latency on the passive avoidance task, in agreement with the results in our previous report (Sato, et al., 2003) , therefore reinforcing the notion that excessive activation of the cAMP/PKA-signaling pathway impairs learning and memory. Because LY341495 is an antagonist of mGlu2 and/or mGlu3 receptors, some think that LY341495 tends to stimulate cAMP formation (Kingston et al., 1998) . In fact, our previous study also showed that excessive administration of forskolin or rolipram decreases latency on the passive avoidance task (Sato et al., 2003) . Donepezil, however, inhibited the reduction of latency induced by LY341495.
The mechanism underlying the ameliorating effect of donepezil is unknown, though we can speculate on some of the possible mechanisms. First, donepezil has been reported to increase the amount of ACh by inhibiting ACHE, thus resulting in increased levels of ACh, which can bind not only with postsynaptic muscarinic M1 receptors but also with presynaptic muscarinic M2 receptors. Therefore, ACh binding to M2 receptors can inhibit ACh release through inhibitory feedback. Consequently, at certain concentrations (achieved by the inhibitory feedback effect on synaptic ACh release), ACh decreases the release of glutamate in the synaptic region (Marchi et al., 1989 
